2023

​

• UNGA week brought numerous announcements and commitments for TB response - here they are!
  
• ​World leaders commit to new targets to end TB
  
• PEPFAR Launches New Effort to Fight TB: Goal to Detect Two Million Cases and Prevent 500,000 Deaths 
  
• ​Global Drug Facility Update on Access to Bedaquiline
  
• ​Call for Proposals: Accelerate and promote responsible introduction of new DR-TB drugs and regimens
  
• ​Presidents of Brazil and France call for increased support to Unitaid to speed up access to lifesaving health products
  
• Adaptation and implementation of the WHO Multisectoral Accountability Framework to end TB: Operational guidance
  
• ​Outbreak of Multidrug-Resistant Tuberculosis — Kansas, 2021–2022
  
• ​WHO strengthens tuberculosis control in Ukraine using high-quality diagnostic methods
  
• ​Lancet Commission Calls for Renewed Global Response on TB 
  
• Johnson & Johnson and Cepheid must pledge access to lifesaving TB medicines and tests
  
• J&J and Cepheid must expand access to TB drug and tests
  
• ​Scientific Advances May End Tuberculosis Outbreaks
  
• ​USAID Launches New Efforts in Fight Against Tuberculosis, Including Additional $23 Million in Funding
  
• Tuberculosis Elimination Alliance Awards Mini-Grants for Tuberculosis Testing, Treatment, and Prevention
  
• ​Open letter to Johnson & Johnson requesting clarification on the recent deal on generic bedaquiline supply
  
• Press Release: Funding Late-Stage Development of M72 TB Vaccine Candidate | Bill & Melinda Gates Foundation
  
• ​Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study - Full Text View - ClinicalTrials.gov
  
• ​TB Online - Germany issues award to IAVI to support development of the MTBVAC TB vaccine candidate
  
• ​TB Online - Urgent action necessary for equitable access to bedaquiline in all countries with high burdens of TB, MDR-TB, and TB/HIV
  
• ​John Green on Twitter: "An open letter to @JNJNews. Stop pursuing the secondary patent of bedaquiline. YOU KNOW that millions of people will be unable to access lifesaving treatment for multidrug-resistant tuberculosis if you extend the patent. YOU KNOW it violates your credo. https://t.co/JArPHWpmv5" / Twitter
  
• ​TB Online - Global Drug Facility update on access to bedaquiline
  
• ​TAG Encouraged by J&J Deal to Reduce Bedaquiline Prices, but Company’s Action Falls Short of Community Demands – Treatment Action Group
  
• TB medicine deal offers short-term solution, but J&J needs to do more for all affected countries | Médecins Sans Frontières Access Campaign
  
• ​Public investments in the clinical development of bedaquiline | PLOS ONE
  
• ​PIH Statement on J&J and Stop TB Deal | Partners In Health
  
• ​J&J expands global access to TB drug amid advocacy campaign
  
• ​Johnson and Johnson shares licence for tuberculosis drug after novelist’s viral campaign | The Independent
  
• Millions could soon have access to lifesaving tuberculosis drug following online uproar - ABC News
  
• ​TDR and WHO announce TDA4Child, an operational research package to generate data on treatment decision algorithms for pulmonary tuberculosis in children
  
• TB Vaccine Candidate Plans Efficacy Study
  
• ​JOINT STATEMENT: WHO DIRECTOR-GENERAL AND THE CIVIL SOCIETY TASK FORCE ON TB FOR THE 2023 UNITED NATIONS HIGH-LEVEL MEETING ON TUBERCULOSIS
  
• ​Mycobacterium Tuberculosis Treatment Market Size, Analysis, Growth ratio, Top Players and Future Forecasts to 2022-2029
  
• ​Task Force Recommends Latent TB Infection Screening
  
• ​Understanding TB Laboratory Testing for Public Health Nurses
  
• ​Preguntas Frecuentes: La Tuberculosis (TB) [Frequently Asked Questions: Tuberculosis (TB)]
  
• ​Screening for Latent Tuberculosis Infection in AdultsUS Preventive Services Task Force Recommendation Statement​
• Uniting for Ukraine Tuberculosis Screening Experience, San Francisco, California, USA
  
• Hope away from home: Providing support for refugees with tuberculosis, wherever they live
  
• Outcomes from a national screening program for Ukrainian refugees at risk of drug resistant tuberculosis in Wales
  
• Tuberculosis Outbreak Among Monkeys in Michigan Laboratory
  
• CDC Quarantine Fails to Detect TB Outbreak; PETA Urges Immediate Action
  
• Joint Statement from the United States and India 
  
• Novel device holds promise for diagnosing tuberculosis in the “missing millions” 
  
• Launch of a second wave of IJTLD Clinical Standards for Lung Health 
  
• READY NEXT TIME Beating TB today and preparing for pandemics tomorrow
  
• QIAGEN’s QuantiFERON-TB Gold Plus shows unique clinical value with CD8 technology in new meta-analysis of tuberculosis screening
  
• TB Notes 2, 2023​
• ​TB is Still Here – New CDC Data Show U.S. Cases Increased Again in 2022
  
• ​With TB Response Rebounding from the COVID-19 Pandemic Downturn, Prime Minister Modi Marks the Start of a New Era on World TB Day:Yes! We Can End TB
  
• ​TB Faded During Covid But Now It’s Back, CDC Data Shows
  
• ​Validation of rapid, molecular testing for COVID-19 and integration with TB diagnostics
  
• ​Short, Effective Drug-Resistant TB Treatment for All Starts Here!
  
• ​WHO Director-General Flagship Initiative to #ENDTB 2023-2027
  
• ​Ending Tuberculosis - the role of Europe in responding to growing challenges
  
• Need for increased global attention on maternal TB: Global TB Report inclusion
  

2022​

​​

• WHO announces plans to establish a TB Vaccine Accelerator council
  
• Worldwide TB R&D Funding Surpasses US$1 Billion, But Falls Short of Goals
  
• Innovative trial finds better treatment for people with drug-resistant TB
  
• Price reduction paves the way for expanded access to highly effective multidrug-resistant tuberculosis treatment
  
• TB-PRACTECAL: Groundbreaking MSF trial finds better treatment for people with drug-resistant tuberculosis
  
• LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test
  
• Innovative TB Community Service Delivery during the COVID-19 Pandemic: Best Practices and Lessons Learned from Cambodia, India, Indonesia, and Kenya
  
• WHO announces landmark changes in treatment of drug-resistant tuberculosis
  
• WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update
  
• FACT SHEET: U.S-Africa Partnership in Health Cooperation
  
• Response to TB treatment trials results published and presented during the 2022 Union World Conference on Lung Health
  
• Pipeline Report » 2022 Tuberculosis Diagnostics
  
• New MSF report warns that major opportunity to increase access to newer, safer DR-TB drugs is at risk
  
• An investment case for new tuberculosis vaccines
  
• Tuberculosis Research Funding Trends 2005 — 2021
  
• WORLDWIDE TB R&D FUNDING SURPASSES US$1 BILLION, BUT FALLS SHORT OF GOALS
  
• Transformative solutions for equitable access to TB services for persons with disabilities
  
• ​Tuberculosis deaths and disease increase during the COVID-19 pandemic
  
• Global Tuberculosis Report 2022
  
• USAID ANNOUNCES EIGHT-YEAR STRATEGY TO END TUBERCULOSIS
  
• Global meeting on strengthening public-private provider engagement calls for greater collaboration with all care providers to get the TB response back-on-track and to enhance accountability
  
• Global Fund Board Hails Record-Breaking Seventh Replenishment Final Outcome of US$15.7 Billion
  
• ​Tuberculosis voice at the G20 - Stop TB Partnership
  
• 1/4/6×24 Campaign
  
• Public Health Leaders, Researchers, and Activists Launch Global Campaign to Revolutionize Tuberculosis Prevention and Treatmnt with New, Shorter, Stronger, Safer, Evidence-Based Regimens
  
• Overview of Notice of Funding Opportunity: Advancing Policy as a Public Health Intervention to Reduce Morbidity, Mortality and Disparities in HIV, Viral Hepatitis, STDs, and Tuberculosis; PS-23-0009
  
• DR-TB Drugs Under the Microscope, 8th Edition
  
• Pipeline Report » 2022 : Tuberculosis Diagnostics
  
• TB Deaths Up Again: Ask Congress to Pass the End TB Now Act
  
• ​UNGA 77: STOP TB HIGHLIGHTS THE NEED FOR ENDING TB
  
• Lupin Partners with Global Agencies to Increase Patient Access to Tuberculosis Prevention Treatment
  
• Illumina and GenoScreen Partner to Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis
  
• Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates
  
• Parliamentarians and Civil Society align on key issues around TB in Migration
  
• PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test
  
• Diversifying the next generation of TB vaccines
  
• WHO announces updates to its guidelines on tests for the diagnosis of TB infection
  
• Four Years Down, One to Go: The Road to the 2023 UN High-Level Meeting on TB
  
• ​TB Alliance Statement on New World Health Organization Rapid Communication on Key Changes to the Treatment of Drug-Resistant Tuberculosis
  
• MSF warns that supply delays of critical TB test will cost lives
  
• The Global Fund Results Report 2022
  
• TB action plan for the WHO European Region 2023–2030
  
• TB Notes 3, 2022: Notes from the Director
  
• The Stop TB Partnership call on governments of donor and high burden TB countries to pledge at least US$18 billion to Global Fund and triple domestic investments in TB
  
• ​U.S. SUPPORTS QUEZON CITY IN FIGHT AGAINST TUBERCULOSIS AND COVID-19
  
•  Addressing Tuberculosis and Latent Tuberculosis Infection Screening, Testing, and Treatment Needs Among Community Health Centers Serving Asian Americans, Native Hawaiians, and Pacific Islanders – September 2022
  
• PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
  
• BioNTech selects Rwanda, Senegal for potential malaria and tuberculosis mRNA vaccine manufacturing
  
• ​High Rates of Chronic Hepatitis B and Tuberculosis Co-Infection Observed in Nationally Representative Quest Diagnostics Study
  
• Mid-term Assessment Summary Report: Global Fund Breaking Down Barriers Initiative, July 2022
  
• ​Community, rights and gender investment packages
  
• 2022 SPECIAL REPORT: COVID-19 - U.S. IMPACT ON ANTIMICROBIAL RESISTANCE
  
• Bacterial vaccines in clinical and preclinical development 2021: An overview and analysis
  
• ​GLOBAL PLAN TO END TB 2023-2030
  
• New, multi-year US$ 5.5 million project will “Re-imagine TB Care”
  
• ​People-Centered, Rights-Based TB Legislation In Eastern Europe and Central Asia
  
• Lack of access to medicine is a major driver of drug resistance. How can pharma take action?
  
• Drug-Resistant Tuberculosis Treatment Market Is Expected to Boom| Sanofi, Novartis AG, Endo International plc, CMP Pharma
  
• WHO Director-General's keynote address at the WHO Global Tuberculosis Programme – 9 June 2022
  
• WHO convenes experts to review methods for estimating TB disease burden
  
• U.S. Government Funded Research Brings Shorter Tuberculosis Treatment Regimens to New York City
  
• Joint Delegation Statement of Community, Developing Country NGOs and Developed Country NGOs
  
• DIGITAL TB SURVEILLANCE SYSTEM ASSESSMENT REPORT
  
• Davos booster for $18 billion fund to fight AIDS, tuberculosis and malaria
  
• ​Rapid communication: Key changes to the treatment of drug-resistant tuberculosis (who.int)
  
• New details behind the body’s response to tuberculosis could lead to a more effective vaccine
  
• Consolidated report of country success stories in mitigating the impact of the COVID-19 pandemic on TB services
  
• ​2022 Epidemic Intelligence Service (EIS) Conference
  
• Methods combine to decode the biology of tuberculosis
  
• Tuberculosis Treatment Drugs Market to See Drastic Growth – Post 2022 | Pfizer, Mylan, Sanofi
  
• ​Global Fund Strategy (2023-2028)
  
• Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure
  
• Management of childhood MDR-TB in Europe and Central Asia: report of a Regional WHO meeting
  
• ​Stop TB Partnership - World TB Day 2022 Campaign Update
  
• IAVI AND MODERNA PARTNER TO TACKLE BROAD GLOBAL HEALTH PRIORITIES USING MRNA FOR VACCINES AND ANTIBODIES
  
• NIH funds new tuberculosis research advancement centers
  
• Report: WHO technical consultation on innovative clinical trial designs for evaluating new TB preventive treatments
  
• ​Media Statement: Effect of COVID-19 on Tuberculosis in the U.S.
  
• March 24, 2022 – COVID-19 likely had a substantial effect on U.S. TB disease trends
  
• ​CROI 2022 TB Round Up
  
• TB disease and deaths declining among people living with HIV, but there have been some reversals due to the COVID-19 pandemic
  
• ​MSF responds to updated WHO guidelines for tuberculosis in children​
  
• Impact of COVID-19 hits hard as TB deaths among people living with HIV rise for the first time since 2006
  
• EU plans to buy measles, polio vaccines for Ukraine refugees
  
• The History of Tuberculosis Holds Lessons For Modern Day Public Health
  
• The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis
  
• Thoracic ultrasound for TB diagnosis in adults and children
  
• Integrated screening and testing for TB and COVID-19 in Peru
  
• INCREASE FUNDING OR ABANDON HOPE OF ENDING MALARIA, TB AND AIDS
  
• Global Fund Approves Emergency Funding to Maintain Essential HIV and TB Services in Ukraine
  
• Multi-center clinical trial launched to investigate new treatment for pediatric type 1 diabetes
  
• ​Worrying lack of funding for tuberculosis
  
• What is the evidence on existing national policies and guidelines for delivering effective tuberculosis, HIV and viral hepatitis services for refugees and migrants among Member States of the WHO European Region? (2022)
  
• European Commitments to TB R&D Investments: Promises Made to Be Broken?
  
• The impact of COVID-19 on TB: a review of the data
  
• Third round of the global pulse survey on continuity of essential health services during the COVID-19 pandemic
  
• Advocates call on Indian government to stop using injectable agents for the treatment of drug-resistant TB
  
• MedMira Receives CE Marking for its REVEALCOVID-19® PLUS Total Antibody Test
  
• QIAGEN’s new generation TB test gets Chinese approval, renewed WHO backing
  
• IN MEMORIUM
  
• FACT SHEET: The Biden Administration’s Commitment to Global Health
  
• ​TB Elimination Alliance Impact Report 2020-2021
  
• Pediatric Tuberculosis Research and Development: Progress, Priorities and Funding Opportunities
  
• Can Patents Affect Access to TB Preventative Treatment
  
• Funding for neglected disease research stays stable in 2020 despite COVID-19 pressures
  
• ​Use of alternative interferon-gamma release assays for the diagnosis of TB infection: WHO policy statement​
  
• With tuberculosis resurgent after two years of COVID-19-inspired neglect, TB Alliance is awarded USAID funding to develop new treatments
  
• WHO: State of inequality: HIV, tuberculosis and malaria
  
• Global Fund Applauds Luxembourg’s Contribution to the COVID-19 Response Mechanism
  
• COVID Deaths in 2021 > Combined Death Toll of HIV, TB, Malaria in 2020   
  
• It’s time for action on inequality to end TB and AIDS
  
• Use of Xpert MTB/RIF and Xpert MTB/RIF Ultra on GeneXpert 10-colour instruments: WHO POLICY STATEMENT
  
• RESIST-TB November 2021 Newsletter
  
• ​NCHHSTP Metrics Dashboard: TB Elimination
  

​2021

• What’s new in the TB section of the 2021 WHO Model Lists of Essential Medicines
• TB bacterium: UAB researcher describe how the exotoxin is secreted and trafficked
  
• Dismal global tuberculosis situation due to COVID-19
  
• U.S., Global Partner Donate Tools to Improve TB Service
  
• GHIT Fund Announces New Investments: A Total of 750 Million Yen in Drugs for Malaria and Chagas Disease, Vaccine for Malaria, and Diagnostics for Tuberculosis
  
• Global Fund Board Approves New Strategy Placing People and Communities at Center to Lead Fight Against HIV, TB, Malaria, to Build Systems for Health, Equity and Strengthen Pandemic Preparedness
  
• ACTG announces launch of clinical trial evaluating a three-month TB treatment
  
• Fighting Pandemics and Building a Healthier and More Equitable World - Global Fund Strategy (2023-2028)
  
• Global Pulmonary Tuberculosis Clinical Trials Report H2, 2021: Phase, Trial Status, End Points Status and Sponsor Type Review - ResearchAndMarkets.com
  
• ACTG Announces Initiation Of CLO-FAST, Its First Trial Evaluating A Three-Month TB Treatment
  
• Research in Action Awards 2021
  
• The Challenge of Diagnosing HIV Infection in LA PrEP Users
  
• PrEPared? Long-Acting PrEP Access in Communities Marginalized by the U.S. Healthcare System
  
• The Lancet Commission on diagnostics: transforming access to diagnostics
  
• Realizing Returns on U.S. Government Investments in GeneXpert Diagnostic Technologies
  
• Long-Acting Therapy for Malaria Prevention: Toward a Malaria-Free World
  
• USAID'S COVID-19 RESPONSE: LATEST NEWS
  
• Terraforming the Policy Landscape to Enable Access to Long-Acting Technologies
  
• Know Your CAB: Community Experts Shaping the Long-Acting Technologies Pipeline
  
• Delivering on the Promise of Long-Acting Technologies
  
• Developing Long-Acting Cures to Accelerate the End of Hepatitis C: Interview with Dr. Dave Thomas
  
• Injectables Redux: Developing Acceptable Long-Acting Formulations for TB Prevention Amidst a Push for All-Oral Treatment
  
• TAG 2021 Pipeline Report Tuberculosis Vaccines
• TAG 2021 Pipeline Report Tuberculosis Preventative Treatment 
• The International Journal of Tuberculosis and Lung Disease
  
• Mapping the Technology Landscape of National TB Programs: Report
  
• Global Lung Health Meet Opens With Top Three Science Announcements
  
• New NACCHO Case Study Series Highlights LHD and Health Center Partnerships to Address TB and COVID-19
  
• WHO Global TB Report Release
  
• People living with HIV who started tuberculosis preventive treatment
  
• Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020
  
• The Medicines Patent Pool secures its first licence on promising long-acting technologies for malaria, tuberculosis, and hepatitis C
  
• Statement on the anniversary of the UN High-Level Meeting on TB
  
• ​Our Footprint at the 52nd Union World Conference on Lung Health
  
• How Can TB Services for Adolescents and Youth be Improved?
  
• A Critical Chance to End Pediatric TB in the Era of COVID-19
  
• TB Alliance Welcomes New Data on BPaL-Based Regimens Presented at the 2021 Union Conference
  
• Rifampicin-Resistant Tuberculosis (RR-TB), MSF Clinical Trials Present Short And Effective Treatment
  
• WHO Global Tuberculosis Report—New Drugs and Regimens Need to be Combined with Equitable and Universal Access
  
• Press Statement: Calls for Urgent Action to Address TB Prevention Deficits Among Children and Household Contacts of People Affected by TB
  
• Anti-tuberculosis Therapeutics Market: Worldwide Analysis and Forecasts, 2021 to 2024
  
• Organic Dispersion To Drive The Drug Resistant Tuberculosis Treatment Market
  
• Reported Tuberculosis in the United States, 2020
  
• Program Evaluation: Developing and Implementing a Remediation Plan1
  
• CDC: TB Notes 3, 2021 - Notes from the Director
  
• ​Meeting report: Virtual Global Forum on Tuberculosis Vaccines, 20–22 April 2021
  
• Tuberculosis Vaccines: An Update of Recent and Ongoing Clinical Trials
  
• Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis
  
• TB Alliance Expands Board of Directors
  
• Public Health Action - September 2021
  
• The Medicines Patent Pool secures its first licence on promising long-acting technologies for malaria, tuberculosis, and hepatitis C
  
• Statement on the anniversary of the UN High-Level Meeting on TB
  
• New Report: The Global Impact of Respiratory Disease - 3rd Edition
• TB Elimination Alliance Impact Report 2020-2021
  
• BMJ Awards 2021: Respiratory team of the year​
• Tuberculosis - Annual Epidemiological Report for 2019
  
• Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis
• Results Report 2021
  
• Policy Research Report - From Siloes to Synergies: Integrating noncommunicable disease prevention and care into global health initiatives and universal health coverage 
  
• Bovine TB: epidemiology reports, 2020
  
• Assembly Side Event: Progress and Multisectoral Action Towards Achieving Global Targets to End TB
  
• ​A second call for case studies of programmatic innovations to address challenges in TB prevention and care during the COVID-19 pandemic
  

​

Where we unite to #EndTB!

Subscribe to the TB WIRE today!

​​​Market Analyses:​

• Global Latent Tuberculosis Infection (LTBI) Testing Market Research Report 2022 - ResearchAndMarkets.com
  
• VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market demand and future scope with Russia-Ukraine Crisis Impact Analysis –Vakzine Projekt Management (VPM), Serum Institute of India
  
• Anti-Tuberculosis Drug Market demand and future scope with Russia-Ukraine Crisis Impact Analysis –Lupin, Otsuka, Sanofi, Prizer, Abbott, NOVARTIS
  
• ​Anti-Tuberculosis Drug Market demand and future scope with Russia-Ukraine Crisis Impact Analysis –Lupin, Otsuka, Sanofi, Prizer, Abbott, NOVARTIS
  
• Tuberculosis Testing Market 2022 By Emerging Trends, Industry Share, Regional Overview and SWOT Analysis till 2027
  
• Tuberculosis Vaccine Treatment Market Size 2021 Analysis by Top Key Players | Sanofi,Merck,Serum Institute of India,GlaxoSmithKline
  
• Tuberculosis (TB) Treatment Market Size 2021 Analysis by Top Key Players | Johnson & Johnson,Otsuka Pharmaceutical Co.,Ltd,Dong-A ST Co.
  
• Tuberculosis Diagnostics Market 2021-2026: Size, Share, Growth, Outlook and Forecast
  
• Anti-tuberculosis Therapeutics 2021 Market by Manufacturers, Regions, Type and Application, Forecast to 2024
  
• Tuberculosis Diagnosis and Treatment Market Size, Key Company Profiles, Types, Applications and Forecast To 2027
  
• Tuberculosis Testing Market Report 2021 Market SWOT Analysis,Key Indicators,Forecast 2027 : Abbott Laboratories, Akonni Biosystems, Alere
  
• Tuberculosis Testing Technology Market to Witness Huge Growth by 2028 | Thermo Fisher Scientific, Alere, Epistem
  
• Global Anti-Tuberculosis Therapeutics Market Industry Share, Size And Movements By Growth Status, Trend Analysis To 2020 – 2027 | Leading Players-Macleods Pharmaceuticals Ltd, Pfizer Inc, Hikma Pharmaceuticals PLC, Lannett, Mylan N.V., Teva Pharmaceutical Industries Ltd
  
• Tuberculosis Drugs Market Trends, Top Manufactures, Tuberculosis Drugs Market Demands, Industry Growth Analysis & Forecast 2026
  
• BCG Vaccine Market By Type (Immune BCG, Therapy BCG), Application Type (Hospitals, Clinics, Others), And Region- Global Forecast To 2028
  
• Global BCG Tuberculosis (TB) Vaccine Market: How Much Will Be the Total Production in 2027? with Top Companies Like:Sanofi Pasteur, Japan BCG Lab, China National Biotec
  
• Tuberculosis Testing Market Innovative Strategy by 2028 | Abbott Laboratories, Akonni Biosystems, Abbott
  
• Tuberculosis Drugs Market CAGR by Technology, Key Players, Regions, Cost, Revenue and Forecast to 2028 | ohnson & Johnson Services, LLC, Lupin Ltd, Novartis AG
  
• Tuberculosis Drugs Competitor Analysis Report - Global Forecast to 2026
• Tuberculosis Diagnostics Competitor Analysis Report - Global Forecast to 2026
  
• Tuberculosis Testing Competitor Analysis Report - Global Forecast to 2026
  
• Tuberculosis Testing Market Industry Analysis, Geographical Segmentation, Drivers, Challenges, Trends Forecasts Report 2021 -2026 – Hoffmann-La Roche AG, Hain LifeScience GmbH, Hologic Corporation, etc.
  
• Tuberculosis Prevention and Treatment Vaccine Market Size 2021 Growing Rapidly with Upcoming Trends, New Development Strategy, Competitive Landscape and Growth by Forecast 2027
  
• Tuberculosis Vaccines Market Professional Survey 2021 by Manufacturers, Share, Growth, Trends, Types and Applications, Forecast to 2026
  
• Tuberculosis Vaccine Treatment Market  Insights, Status, Latest Amendments and Outlook 2021 – 2027 |Top key players: Merck & Co., Inc.(US), Sanofi Pasteur SA (France)
  
• Tuberculosis Vaccine Treatment Market SWOT Analysis,Key Indicators,Forecast 2027 : Merck,Japan BCG Lab,Serum Institute of India,AJ Vaccines
  
• Tuberculosis Vaccine Treatment Market Growth Factor Details for Business Development Forecasts 2027 – Serum Institute of India, AJ Vaccines
  
• Tuberculosis Treatment Market 2021-2027 Global Industry Outlook- Sanofi, Bayer, Eli Lilly, Labatec Pharma, Novatis
  
• Tuberculosis Treatment Drugs Market 2021 | Scope of Current and Future Industry 2027
  
• Tuberculosis Testing Market Drivers And Restraints For Each Segment
  
• Tuberculosis Drugs Market Ultimate Analysis by Source, Sales Channel, Formulation & Global Forecast to 2027
  
• Tuberculosis Drugs Market Size 2021 Key Strategies, Applications, Trends and Opportunities
  
• Tuberculosis Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
  
• Tuberculosis (TB) Treatment Market Size, Latest Trends, Growth and Share 2021 | Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd, Macleods Pharmaceutical Ltd
• Mycobacterium Tuberculosis Market Future Outlook of Statistics on Industry Growth till 2026| Thermo Fisher Scientific, Danaher, Mediven, Osang Healthcare, Hologic
  
• GLOBAL TUBERCULOSIS VACCINE TREATMENT MARKET REPORT FUTURE PROSPECTS, GROWTH, OUTLOOK AND FORECAST 2021-2026
  
• Global Tuberculosis Therapeutics Market Statistics, Development and Growth Market Players 2022-2027
  
• Global Tuberculosis Drugs Market Development Prospects 2021-2027 | By Pfizer Inc, Cipla Ltd, AstraZeneca Plc, Novartis AG
  
• Tuberculosis Diagnosis and Treatment Market Size and Industry Analysis Report, by Type, by Application, by Country & Region, and Segment Forecasts, 2016 – 2027
  
• Infectious Disease Molecular Diagnostics Market Size Worth $40.8 Billion By 2028: Grand View Research, Inc. 
  
• Tuberculosis Testing Technology Market (2021-2027) Demand Analysis, Global Business Growth | F. Hoffmann-La Roche AG, QIAGEN, Cepheid Inc., Hologic, Sanofi S.A., Abbott Laboratories, BioMérieux, Thermo Fisher Scientific, etc 
  
• TB Vaccines Market Major Geographies, Prominent Players Review and Forecast 2021 to 2027
  
• Tuberculosis Treatment Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth
  
• TUBERCULOSIS VACCINE TREATMENT MARKET ANALYSIS BY SIZE, SHARE, GROWTH, APPLICATION, SEGMENTATION AND FORECAST TO 2026
  
• LATENT TUBERCULOSIS TESTING MARKET SHARE TO RECORD ROBUST GROWTH THROUGH 2026
  
• Tuberculosis Testing Market Size,Forecast,and Top Firms : Abbott Laboratories,Akonni Biosystems,Alere,,Becton,Dickinson and Company,Cepheid​
  
• Global Tuberculosis (TB) Detection Market Growing Popularity and Emerging Trends 2021-2028 Danaher, Hain Lifescience, Abbott
• Global Tuberculosis (TB) Detection Market Growing Popularity and Emerging Trends 2021-2028 Danaher, Hain Lifescience, Abbott
  
• Tuberculosis Treatment Market Size, Share, Future Opportunities 2028 | Sanofi, Otsuka, Labatec Pharma, Bayer, Novatis, Eli Lilly, Pfizer, etc.
  
• Qualitative analysis of Tuberculosis Testing and Diagnostics Market Revenue & Industry Analysis By 2026
  
• Tuberculosis Testing Market research and analysis by expert top companies, growth drivers, industry challenges, and opportunities to 2028
  
• Global Anti-Tuberculosis Therapeutics Market Forecast to 2027 Size, Share, Upcoming Trends Segmentation, Top Players like Lupin, Johnson and Johnson Services Inc, Macleods Pharmaceuticals Ltd, Pfizer Inc, Hikma Pharmaceuticals
  
• Global BCG Tuberculosis Vaccine Market Report Forecast to 2021-27- GREENSIGNAL BIO PHARMA LIMITED, INTERVAX LTD, JAPAN BCG LABORATORY
  
• Tuberculosis Drugs Market to Eyewitness Massive Growth by EIKEN CHEMICAL, Sandoz, Archivel Farma
  

​